Ovid Therapeutics Valuation
| OVID Stock | USD 1.09 0.01 0.91% |
Today, the company appears to be undervalued. Ovid Therapeutics holds a recent Real Value of $2.36 per share. The prevailing price of the company is $1.09. Our model determines the value of Ovid Therapeutics from analyzing the company fundamentals such as Current Valuation of 30.47 M, return on equity of -0.37, and Shares Owned By Insiders of 15.89 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Ovid Therapeutics' valuation include:
Price Book 1.0239 | Enterprise Value 30.5 M | Enterprise Value Ebitda (0.69) | Price Sales 123.6529 | Forward PE 1.7918 |
Undervalued
Today
Please note that Ovid Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Ovid Therapeutics is based on 3 months time horizon. Increasing Ovid Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Ovid stock is determined by what a typical buyer is willing to pay for full or partial control of Ovid Therapeutics. Since Ovid Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ovid Stock. However, Ovid Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.09 | Real 2.36 | Target 6.25 | Hype 1.09 |
The real value of Ovid Stock, also known as its intrinsic value, is the underlying worth of Ovid Therapeutics Company, which is reflected in its stock price. It is based on Ovid Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ovid Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ovid Therapeutics helps investors to forecast how Ovid stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ovid Therapeutics more accurately as focusing exclusively on Ovid Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Ovid Therapeutics' intrinsic value based on its ongoing forecasts of Ovid Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Ovid Therapeutics' closest peers. If more than one evaluation category is relevant for Ovid Therapeutics we suggest using both methods to arrive at a better estimate.
Ovid Therapeutics Cash |
|
Ovid Valuation Trend
Comparing Ovid Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Ovid Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Ovid Therapeutics Total Value Analysis
Ovid Therapeutics is now forecasted to have valuation of 30.47 M with market capitalization of 78.11 M, debt of 16 M, and cash on hands of 152.37 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Ovid Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
30.47 M | 78.11 M | 16 M | 152.37 M |
Ovid Therapeutics Investor Information
About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.02. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Ovid Therapeutics recorded a loss per share of 0.46. The entity had not issued any dividends in recent years. Based on the key indicators related to Ovid Therapeutics' liquidity, profitability, solvency, and operating efficiency, Ovid Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Ovid Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ovid Therapeutics has an asset utilization ratio of 0.27 percent. This indicates that the Company is making $0.00272 for each dollar of assets. An increasing asset utilization means that Ovid Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Ovid Therapeutics Ownership Allocation
Ovid Therapeutics owns a total of 71.01 Million outstanding shares. Over half of Ovid Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Ovid Therapeutics Profitability Analysis
The company reported the previous year's revenue of 391.69 K. Net Loss for the year was (52.34 M) with profit before overhead, payroll, taxes, and interest of 1.5 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Ovid Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Ovid Therapeutics and how it compares across the competition.
About Ovid Therapeutics Valuation
The stock valuation mechanism determines Ovid Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Ovid Therapeutics. We calculate exposure to Ovid Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ovid Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 391.7 K | 372.1 K | |
| Pretax Profit Margin | (133.62) | (126.94) | |
| Operating Profit Margin | (151.35) | (143.78) | |
| Net Loss | (133.62) | (126.94) | |
| Gross Profit Margin | 0.07 | 0.06 |
Ovid Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Ovid Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 70.6 M | |
| Forward Price Earnings | 1.7918 |
Ovid Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Ovid Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Ovid we look at many different elements of the entity such as Ovid's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Ovid Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Ovid Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Ovid Therapeutics' worth.Complementary Tools for Ovid Stock analysis
When running Ovid Therapeutics' price analysis, check to measure Ovid Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ovid Therapeutics is operating at the current time. Most of Ovid Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ovid Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ovid Therapeutics' price. Additionally, you may evaluate how the addition of Ovid Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |